What is the bioavailability of Clevatess?

Understanding Clevatess Bioavailability

What is the bioavailability of Clevatess? Clevatess (clofarabine) demonstrates excellent bioavailability when administered intravenously, with nearly 100% systemic availability due to its direct delivery into the bloodstream.

Pharmacokinetic Profile

Clevatess exhibits predictable pharmacokinetic characteristics that make it highly effective for treating acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The medication bypasses first-pass metabolism in the liver because it's administered intravenously, ensuring maximum drug concentration reaches target tissues.

Absorption and Distribution

Following intravenous administration, Clevatess rapidly distributes throughout body tissues, with peak plasma concentrations achieved immediately after infusion completion. The drug demonstrates a volume of distribution of approximately 172 L/m², indicating extensive tissue penetration, which is crucial for reaching leukemic cells in various body compartments.

Elimination Characteristics

The bioavailability profile of Clevatess is further characterized by its elimination half-life of approximately 5.2 hours. The drug undergoes minimal hepatic metabolism, with approximately 49-60% eliminated unchanged through renal excretion. This elimination pattern makes dose adjustments necessary for patients with kidney impairment.

Clinical Implications

The high bioavailability of Clevatess ensures consistent therapeutic drug levels, contributing to its efficacy in treating relapsed or refractory acute leukemias in pediatric and young adult patients. Healthcare providers can rely on predictable drug exposure when calculating appropriate dosing regimens.

Factors Affecting Bioavailability

While Clevatess maintains consistent bioavailability in most patients, factors such as renal function, age, and concurrent medications may influence drug exposure. Regular monitoring helps optimize treatment outcomes while minimizing potential adverse effects.

Understanding Clevatess bioavailability is essential for healthcare professionals managing leukemia patients. For detailed prescribing information and patient-specific dosing considerations, consult with your oncology specialist or review the complete prescribing information.